[go: up one dir, main page]

AR122058A1 - Usos y formulaciones de cannabinoides - Google Patents

Usos y formulaciones de cannabinoides

Info

Publication number
AR122058A1
AR122058A1 ARP210101283A ARP210101283A AR122058A1 AR 122058 A1 AR122058 A1 AR 122058A1 AR P210101283 A ARP210101283 A AR P210101283A AR P210101283 A ARP210101283 A AR P210101283A AR 122058 A1 AR122058 A1 AR 122058A1
Authority
AR
Argentina
Prior art keywords
cannabinoids
formulations
cannabidiol
patients suffering
inflammatory conditions
Prior art date
Application number
ARP210101283A
Other languages
English (en)
Inventor
Reinhard Nowak
Mirko Nowak
Jesko Jay Nowak
Pllinger Norbert Dr
Original Assignee
Add Advanced Drug Delivery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Add Advanced Drug Delivery Tech Ltd filed Critical Add Advanced Drug Delivery Tech Ltd
Publication of AR122058A1 publication Critical patent/AR122058A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan usos y formulaciones de cannabinoides, en particular de cannabidiol. Los cannabinoides, en particular el cannabidiol, se utilizan para el tratamiento de pacientes que padecen afecciones inflamatorias asociadas con enfermedades autoinmunes, enfermedades inflamatorias crónicas y afecciones inflamatorias relacionadas con infecciones, incluido el síndrome de liberación de citoquinas (CRS). Las formulaciones son especialmente para la administración oral de cannabinoides, en particular de cannabidiol. Estas formulaciones son útiles para tratar a pacientes que padecen las afecciones mencionadas con anterioridad.
ARP210101283A 2020-05-11 2021-05-11 Usos y formulaciones de cannabinoides AR122058A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2020/063087 WO2021228366A1 (en) 2020-05-11 2020-05-11 Uses and formulations of cannabinoids

Publications (1)

Publication Number Publication Date
AR122058A1 true AR122058A1 (es) 2022-08-10

Family

ID=70861444

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101283A AR122058A1 (es) 2020-05-11 2021-05-11 Usos y formulaciones de cannabinoides

Country Status (10)

Country Link
US (1) US20230201284A1 (es)
EP (1) EP4149446A1 (es)
JP (1) JP2023534362A (es)
CN (1) CN115605190A (es)
AR (1) AR122058A1 (es)
AU (1) AU2020447169A1 (es)
BR (1) BR112022021646A2 (es)
CA (1) CA3182923A1 (es)
IL (1) IL298059A (es)
WO (1) WO2021228366A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3181645A1 (en) * 2020-05-11 2021-11-18 Add Advanced Drug Delivery Technologies Ltd. Uses and formulations of cannabinoids

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807639D0 (en) * 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
EP3001812B1 (en) 2013-10-29 2016-11-02 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
WO2017072774A1 (en) * 2015-10-29 2017-05-04 Solubest Ltd Pharmaceutical compositions for transmucosal delivery
WO2018035030A1 (en) 2016-08-15 2018-02-22 Corr-Jensen Inc. Time release fat-soluble actives
WO2019155337A1 (en) * 2018-02-06 2019-08-15 Scicann Therapeutics Inc. Compositions comprising a cannabinoid and punicalagin and methods of use thereof
EP3823596A2 (en) * 2018-07-18 2021-05-26 Glatt Gmbh Extended release formulations of cannabinoids
EP3643303A1 (en) * 2018-10-22 2020-04-29 InnovativeHealth Group SL Compounds for use in the treatment or prevention of fibrotic diseases; pharmaceutical, cosmetic compositions and uses thereof

Also Published As

Publication number Publication date
CA3182923A1 (en) 2021-11-18
WO2021228366A1 (en) 2021-11-18
US20230201284A1 (en) 2023-06-29
AU2020447169A1 (en) 2022-12-08
IL298059A (en) 2023-01-01
CN115605190A (zh) 2023-01-13
BR112022021646A2 (pt) 2022-12-13
EP4149446A1 (en) 2023-03-22
JP2023534362A (ja) 2023-08-09

Similar Documents

Publication Publication Date Title
MX2022001337A (es) Uso de cannabidiol en el tratamiento del sindrome de dravet.
MX2020009246A (es) Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular.
MX2021008702A (es) Uso de cannabinoides en el tratamiento de las comorbilidades asociadas a la epilepsia.
MX2020005719A (es) Uso de cannabinoides en el tratamiento de epilepsia.
CL2023002895A1 (es) Anticuerpos anti-il-2r agonistas y métodos de uso
MX2025007468A (es) Composiciones y metodos para el manejo de trastornos
AR122059A1 (es) Usos y formulaciones de cannabinoides
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
MX2019015315A (es) Composiciones y tratamientos para el trastorno del sueño.
ECSP066972A (es) Profármacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y métodos
CL2021002646A1 (es) Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicosactivos
AR034746A1 (es) Combinaciones para el tratamiento de trastornos inflamatorios
MX2021003110A (es) Agonistas del receptor x farnesoide y usos de los mismos.
WO2020044119A3 (en) Oral formulations of lavender and cannabinoids
DOP2001000294A (es) Combinación de agonistas de gaba e inhibidores de aldosa-reductasa
CL2022003507A1 (es) Composición y método para tratar el dolor crónico
AR057946A1 (es) Formulacion de zonisamida de liberacion sostenidda
MX2021014189A (es) Regimenes de dosificacion de agonistas de la il-2/il-15r?y para el tratamiento del cancer o enfermedades infecciosas.
CL2025000581A1 (es) Estructuras derivadas de tn3 específicas de cd40l; tratamiento, prevención del síndrome de sjögren
ECSP22036455A (es) Inhibidores del factor d del complemento para administraci?n oral
CL2021000882A1 (es) Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia.
AR122058A1 (es) Usos y formulaciones de cannabinoides
MX2022014197A (es) Usos y formulaciones de cannabinoides.
CL2022002239A1 (es) Tafoxiparina para el tratamiento de la preeclampsia
CL2025002105A1 (es) Proteínas de fusión fc de il-12